Melbourne, Australia
Optain is an international MedTech company, founded in 2023, with a focus on developing advanced AI software solutions. The company's slogan, "Optain's AI software analyses full-colour fundus images to screen for referable eye diseases including glaucoma," reflects its core offering.
Optain's flagship product, Eyetelligence Assure software, utilizes AI to analyze full-colour fundus images to screen for referable eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration. Moreover, the technology extends its screening capabilities to include cardiovascular diseases and provide a risk assessment profile.
The last investment in Optain amounted to $12.00M in a Seed Round led by Aegis Ventures and Northwell Holdings on 09 May 2023. Headquartered in Australia, Optain envisions harnessing the power of AI to provide affordable clinical support tools, making disease screening accessible anytime, anywhere. With its strong focus on addressing critical health care needs, Optain is poised to make a significant impact in the Health Care and Medical Devices industries.
